Sector Gamma AS Has $15.04 Million Holdings in Biogen Inc. $BIIB

Sector Gamma AS lifted its position in Biogen Inc. (NASDAQ:BIIB) by 13.2% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 85,475 shares of the biotechnology company’s stock after buying an additional 10,000 shares during the quarter. Biogen comprises 3.4% of Sector Gamma AS’s investment portfolio, making the stock its 9th largest holding. Sector Gamma AS’s holdings in Biogen were worth $15,043,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in BIIB. Caprock Group LLC bought a new stake in Biogen during the third quarter worth approximately $742,000. Leuthold Group LLC bought a new stake in Biogen during the third quarter worth approximately $3,294,000. Generali Investments Management Co LLC boosted its position in Biogen by 408.2% during the third quarter. Generali Investments Management Co LLC now owns 9,970 shares of the biotechnology company’s stock worth $1,397,000 after purchasing an additional 8,008 shares during the period. SG Americas Securities LLC boosted its position in Biogen by 1,793.8% during the fourth quarter. SG Americas Securities LLC now owns 183,829 shares of the biotechnology company’s stock worth $32,352,000 after purchasing an additional 174,122 shares during the period. Finally, TD Asset Management Inc boosted its position in Biogen by 12.7% during the third quarter. TD Asset Management Inc now owns 161,195 shares of the biotechnology company’s stock worth $22,580,000 after purchasing an additional 18,168 shares during the period. Institutional investors own 87.93% of the company’s stock.

Biogen Stock Up 2.9%

BIIB opened at $199.96 on Friday. Biogen Inc. has a 1-year low of $121.05 and a 1-year high of $205.97. The company has a current ratio of 3.06, a quick ratio of 2.41 and a debt-to-equity ratio of 0.34. The stock has a market capitalization of $29.52 billion, a price-to-earnings ratio of 21.45 and a beta of 0.20. The business has a 50 day moving average of $188.40 and a 200-day moving average of $184.20.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings data on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share for the quarter, beating the consensus estimate of $2.95 by $0.62. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The company had revenue of $2.48 billion during the quarter, compared to analysts’ expectations of $2.29 billion. During the same period in the prior year, the business earned $3.02 earnings per share. Biogen’s revenue for the quarter was up 1.9% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. As a group, sell-side analysts anticipate that Biogen Inc. will post 14.18 earnings per share for the current year.

Biogen News Roundup

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: At Biogen’s 2026 annual meeting, shareholders backed the board, auditor, and pay-related proposals, signaling continued investor support for management and governance. Biogen Shareholders Back Board, Auditor and Pay Policies
• Positive Sentiment: Biogen has recently outperformed other biotech stocks, with commentary noting that analysts remain reasonably upbeat about its prospects. How Is Biogen’s Stock Performance Compared to Other Biotech Stocks?
• Neutral Sentiment: Denali Therapeutics highlighted that it halted joint work with Biogen on BIIB122 for Parkinson’s disease after Phase 2b results, which appears to be a program setback but is not necessarily a direct blow to Biogen’s broader business. What Makes Denali Therapeutics (DNLI) One of the Best AI Driven Biotech Names
• Negative Sentiment: Two shareholder-law firms, Schall and Pomerantz, announced investigations into possible false or misleading statements by Biogen, increasing the risk of litigation headlines and potential investor uncertainty. BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Investigation with the Schall Law Firm INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. – BIIB
• Negative Sentiment: MarketWatch also noted that Biogen underperformed peers on Wednesday, suggesting the stock has been lagging some competitors despite its recent longer-term strength. Biogen Inc. stock underperforms Wednesday when compared to competitors

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. Weiss Ratings raised Biogen from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, May 1st. Morgan Stanley upped their target price on Biogen from $200.00 to $206.00 and gave the stock an “equal weight” rating in a research report on Thursday, April 30th. Guggenheim upped their target price on Biogen from $246.00 to $260.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. Truist Financial decreased their target price on Biogen from $193.00 to $189.00 and set a “hold” rating for the company in a research report on Monday, April 13th. Finally, HSBC upped their target price on Biogen from $143.00 to $150.00 and gave the stock a “reduce” rating in a research report on Tuesday, March 17th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Biogen currently has a consensus rating of “Moderate Buy” and a consensus target price of $217.26.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.